Home›Dermatology› Ustekinumab May Improve Inverse Psoriasis in Single Case Report
Ustekinumab May Improve Inverse Psoriasis in Single Case ReportUstekinumab Shows Promise for Treatment of Inverse Psoriasis
Frontiers in MedicinePublished September 10, 2026Study authors: Yongjun Chen, Jingjing Liu, Yunhan Hu, Ting YangDOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret single-case ustekinumab response in inverse psoriasis as hypothesis-generating only.
This publication is a single case report describing a 32-year-old male patient with inverse psoriasis who received four subcutaneous injections of ustekinumab. The primary outcome was improvement of skin lesions and pruritus, with follow-up reported at 24 weeks.
The authors report marked improvement in skin lesions and pruritus. No effect size, absolute numbers, p-values, or confidence intervals were reported. No comparator was used.
Safety data were not reported, including adverse events, serious adverse events, discontinuations, and tolerability. Funding and conflicts of interest were also not reported.
The authors acknowledge the limitation of a single case report. They suggest that ustekinumab may represent a novel therapeutic approach for inverse psoriasis, but this claim is explicitly flagged as not to be overstated. The evidence is insufficient to support changes in clinical practice or to draw conclusions about efficacy or safety in the broader inverse psoriasis population.
How this fits prior evidence
Prior coverage has established ustekinumab as an approved therapy for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, with weight-based dosing considerations. Other prior items note that ustekinumab reduces fatigue and arthritis/arthralgia in Crohn's disease and that IL-17 inhibitors rank highly for clearance of scalp, nail, and palmoplantar psoriasis. This case report extends the discussion to inverse psoriasis, a difficult-to-treat site, but provides only anecdotal evidence. It does not confirm or contrast with the comparative efficacy data from prior network meta-analyses, and no safety or dosing comparisons can be made from this single case.
A recent case report looked at how a 32-year-old man responded to a medication called ustekinumab. The patient had a skin condition known as inverse psoriasis. He received four subcutaneous injections of the medication over a period of time.
After 24 weeks of treatment, the patient showed marked improvement in both his skin lesions and his itching. While the results for this specific individual were positive, it is important to note that this was a single case report. This means the study only observed one person rather than a large group.
Because this is a single case, the results cannot be used to confirm how well the drug works for everyone. However, it suggests that ustekinumab could be a potential option for people dealing with inverse psoriasis. You should talk to your doctor to see if this treatment is right for your specific needs.
What this means for you:
A single case shows ustekinumab improved skin lesions and itching in a patient with inverse psoriasis.
Common questions
What is inverse psoriasis?
Inverse psoriasis is a type of skin condition that often affects skin folds. In this specific case, a 32-year-old male patient was treated for this condition. The study focused on how his skin lesions and itching improved after receiving four injections of ustekinumab.
How did the patient respond to ustekinumab?
The patient received four subcutaneous injections of ustekinumab. After a follow-up period of 24 weeks, the patient showed marked improvement in both his skin lesions and his pruritus, which is the medical term for itching.
Can this treatment work for everyone with psoriasis?
Because this was a single case report involving only one patient, the results cannot be applied to everyone. While the treatment was successful for this individual, you should consult a healthcare professional to determine the best treatment plan for your specific condition.
Inverse psoriasis is a relatively rare and distinct subtype of psoriasis whose pathogenesis remains incompletely understood. The particular location of lesions presents significant therapeutic challenges, and no consensus guidelines are currently available. Immune mediated inflammation plays a key role in disease development. Lesions are susceptible to riction and moisture, which reduces treatment tolerance in affected areas. We report a case of a 32-year-old male patient with inverse psoriasis successfully treated with ustekinumab. The patient received four subcutaneous injections of ustekinumab, and after 24 weeks of treatment, both skin lesions and pruritus showed marked improvement. Our experience suggests that ustekinumab may represent a novel therapeutic approach for this psoriasis subtype.
